Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 12:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ublituximab Clear all
Recruiting Phase 4 Interventional

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

NCT07389590
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
TGR-1202, TGR-1202 + Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

NCT02656303
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ublituximab, Umbralisib
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Huntsville, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
No Intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
109
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

NCT06433765
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Active, not recruiting No phase listed Observational

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

NCT06143514
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
No intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Francisco, California • Smyrna, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Completed Phase 1 Interventional Results available

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

NCT02276963
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 27, 2026, 12:41 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

NCT04016805
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ublituximab, Umbralisib, Ibrutinib, Venetoclax, Acalabrutinib Oral Capsule
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 27, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

NCT04783415
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Ublituximab, Umbralisib
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Terminated Phase 1 Interventional

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04806035
View directory record Official record
Conditions
CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL
Interventions
TG-1801, Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 27, 2026, 12:41 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting Early Phase 1 Interventional

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

NCT06629428
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Recruiting Phase 4 Interventional

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 27, 2026, 12:41 PM EDT
Not yet recruiting Phase 2 Interventional

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181
View directory record Official record
Conditions
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Jonathan Santoro
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 27, 2026, 12:41 PM EDT